3 days Ago By ABMN Staff
Amgen ( NASDAQ:AMGN – Get Free Report ) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Thursday. Several other equities analysts have also weighed in on AMGN.
Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Truist Financial decreased their price target on Amgen from $333.00 to $298.
00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Piper Sandler boosted their price objective on shares of Amgen from $310.00 to $329.
00 and gave the company an “overweight” rating in a report on Monday, February 10th. Bank of America boosted their price target on shares of Amgen from $275.00 to $294.
00 and gave the company an “underperform” rating in a research note on Wednesday, March 5th. Finally, Citigroup restated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock.
According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $314.91.
Get Our Latest Report on AMGN Amgen Price Performance Amgen ( NASDAQ:AMGN – Get Free Report ) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.
04 by $0.27. Amgen had a return on equity of 176.
32% and a net margin of 12.24%. On average, equities analysts predict that Amgen will post 20.
62 earnings per share for the current fiscal year. Insider Buying and Selling In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th.
The shares were sold at an average price of $304.47, for a total transaction of $483,802.83.
Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.
06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link . Also, EVP David M.
Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.
00. Following the completion of the sale, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68.
This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Over the last 90 days, insiders have sold 69,341 shares of company stock valued at $20,644,335. Corporate insiders own 0.69% of the company’s stock.
Institutional Inflows and Outflows Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital World Investors boosted its position in Amgen by 1,292.0% during the fourth quarter.
Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after acquiring an additional 6,029,058 shares during the last quarter. Norges Bank purchased a new position in Amgen during the fourth quarter worth about $1,541,991,000. GAMMA Investing LLC boosted its stake in Amgen by 43,573.
5% in the 1st quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock worth $1,140,768,000 after buying an additional 3,653,205 shares during the last quarter. Capital International Investors increased its stake in shares of Amgen by 40.
1% during the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after acquiring an additional 3,495,503 shares during the last quarter. Finally, Charles Schwab Investment Management Inc.
lifted its holdings in shares of Amgen by 25.4% during the 4th quarter. Charles Schwab Investment Management Inc.
now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
About Amgen ( Get Free Report ) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Featured Stories Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.
com's FREE daily email newsletter ..
